Topics
March 2012 | Perspectives: from The Editors Of New Retina Md
The Sunshine Act's Intimidation Factor
Will the noble objectives of this law set up a roadblock to innovation?
Richard S. Kaiser, MD, and Jonathan L. Prenner, MD
August 6, 2026
Norlase Expands European Footprint
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals
August 5, 2026
Vantage Biosciences Completes Enrollment in Phase 2 SeeClear Trial of Oral NPDR Therapy
August 4, 2026
University of Iowa Research Underpins First-in-Human UK Study of Gene Therapy Targeting Rare IRD
July/August 2026 Insert
Editorially independent supported by Abbvie and Regenxbio
July/August 2026 Supplement
Editorially Independent Content, Supported With Advertising From Astellas and ZEISS
July 2026 Supplement
Free Print Subscription
Email Newsletter
Conference Calendar
_1784132761.jpg?auto=compress,format&w=70)
